How to Administer Triple Antithrombotic Therapy in Patients Already on NOACs
For patients already on a NOAC who require PCI, you should NOT routinely give triple therapy (NOAC + aspirin + P2Y12 inhibitor); instead, use double therapy (NOAC + P2Y12 inhibitor) as the default strategy, reserving triple therapy only for highly selected high-risk patients for a maximum of 1 month. 1
The Default Strategy: Double Therapy
The evidence strongly supports double therapy (NOAC + clopidogrel) started immediately at hospital discharge as the preferred approach for most patients. 1 This strategy significantly reduces bleeding complications without increasing thrombotic events compared to traditional triple therapy. 2
Peri-PCI Management
- During the PCI procedure itself: Give aspirin (325 mg loading dose if aspirin-naïve) along with your NOAC and P2Y12 inhibitor loading dose (clopidogrel 600 mg). 1
- At hospital discharge: Transition immediately to double therapy (NOAC + clopidogrel 75 mg daily), discontinuing aspirin. 1
- The rationale: Aspirin's irreversible COX-1 binding provides residual antiplatelet effects for 7-10 days after the peri-PCI dose, making continued aspirin unnecessary. 1
When to Consider Triple Therapy (Rare Exception)
Triple therapy may be reasonable ONLY in patients who are:
- High ischemic/thrombotic risk (e.g., acute coronary syndrome, complex PCI, left main stenting)
- AND low bleeding risk (HAS-BLED score considerations)
- Duration: Maximum 1 month post-PCI, rarely beyond 1
Risk-Stratified Algorithm
High Ischemic/Thrombotic Risk + Low Bleeding Risk:
- Peri-PCI: NOAC + aspirin + P2Y12 inhibitor
- 0-1 month: Continue triple therapy (up to 1 month maximum)
- 1-12 months: Switch to double therapy (NOAC + clopidogrel)
12 months: NOAC monotherapy
Low Ischemic/Thrombotic Risk OR High Bleeding Risk (MOST PATIENTS):
- Peri-PCI: NOAC + aspirin + P2Y12 inhibitor
- At discharge: Immediately switch to double therapy (NOAC + clopidogrel)
- 6-12 months: Continue double therapy
12 months: NOAC monotherapy 1
Specific Drug Choices
P2Y12 Inhibitor Selection
- Clopidogrel is the preferred P2Y12 inhibitor due to lower bleeding risk compared to more potent agents. 1
- Ticagrelor may be considered in high ischemic/low bleeding risk patients, but if used, do NOT add aspirin (avoid triple therapy with ticagrelor). 1
- Prasugrel is NOT recommended due to nearly 4-fold increase in bleeding with triple therapy. 1
NOAC Dosing
- Use full stroke-prevention doses of your NOAC during double/triple therapy
- Exception: Rivaroxaban uses reduced doses (15 mg daily, or 10 mg if CrCl 30-50 mL/min) during combination therapy, then resume full dose (20 mg daily) after stopping antiplatelet therapy. 1
Aspirin Dosing (if used)
- Loading: 325 mg
- Maintenance: 75-100 mg daily (low-dose only) 1
Critical Pitfalls to Avoid
Do NOT continue triple therapy beyond 1 month except in extraordinary circumstances—bleeding risk escalates dramatically (2-3 fold increase with DAPT added to OAC). 3
Do NOT use prasugrel in combination with NOACs—bleeding risk is unacceptably high. 1
Do NOT forget to adjust rivaroxaban dosing when transitioning from combination therapy to monotherapy. 1
Do NOT use platelet function or genetic testing to guide P2Y12 inhibitor selection—this is not recommended. 1
Do NOT use full-dose triple therapy routinely—the evidence conclusively shows double therapy is safer without compromising efficacy. 2
Duration Summary Table
| Time Period | High Risk/Low Bleeding | Low Risk/High Bleeding |
|---|---|---|
| Peri-PCI | Triple therapy | Triple therapy |
| Discharge-1 month | Triple therapy (up to 1 month) | Double therapy |
| 1-6 months | Double therapy | Double therapy |
| 6-12 months | Double therapy | Consider stopping P2Y12i at 6 months |
| >12 months | NOAC monotherapy | NOAC monotherapy |
The evidence from multiple randomized trials demonstrates that this double therapy approach reduces clinically significant bleeding by approximately 44% (HR 0.56) without increasing major adverse cardiac events. 2 This represents a paradigm shift from historical triple therapy practices that significantly increased bleeding complications, including major bleeding rates of 4-12% at 1 year. 3